Alternative splicing in chronic myeloid leukemia (CML): A novel therapeutic target?

Current Cancer Drug Targets

Volumn 13, Issue 7, 2013, Pages 735-748

  Adamia, Sophia ^a   Pilarski, Patrick M ^b   Bar Natan, Michal ^c   Stone, Richard M ^a   Griffin, James D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

Alternative splicing; BCR ABL; Bio markers; Chronic myeloid leukemia; Therapeutic targets

Indexed keywords

AMILORIDE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; CD44V ANTIGEN; CD44V6 ANTIGEN; GLYCOGEN SYNTHASE KINASE 3BETA; HERBOXIDIENE; HERMES ANTIGEN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; IMATINIB; INTERFERON REGULATORY FACTOR 1; ISOGINKGETIN; ISOPROTEIN; MESSENGER RNA; MICRORNA; PLADIENOLIDE B; PROTEIN MDM2; PROTEIN P53; PROTEIN VARIANT; PROTEIN WT1; SERINE ARGININE RICH PROTEIN; SERINE ARGININE RICH SPLICING FACTOR 3; SMALL NUCLEAR RIBONUCLEOPROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GROWTH FACTOR INDEPENDENT 1B; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; APOPTOSIS; ARTICLE; BREAKPOINT CLUSTER REGION GENE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DISEASE MARKER; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; EPIGENETICS; EXON; GENE EXPRESSION; HUMAN; INTRON; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SPLICEOSOME;

ALTERNATIVE SPLICING; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; RNA PRECURSORS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84888053798     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113139990083     Document Type: Article

References (156)

1. Ast, G. How did alternative splicing evolve? Nat. Rev. Genet. 2004, 5 (10), 773-782.
2. Abrahamsson, A. E.; Geron, I.; Gotlib, J.; Dao, K. H.; Barroga, C. F.; Newton, I. G.; Giles, F. J.; Durocher, J.; Creusot, R. S.; Karimi, M.; Jones, C.; Zehnder, J. L.; Keating, A.; Negrin, R. S.; Weissman, I. L.; Jamieson, C. H. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (10), 3925-3929.
3. Brown, R. L.; Reinke, L. M.; Damerow, M. S.; Perez, D.; Chodosh, L. A.; Yang, J.; Cheng, C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J. Clin. Invest. 2011, 121 (3), 1064-1074.
4. Lo, T. C.; Barnhill, L. M.; Kim, Y.; Nakae, E. A.; Yu, A. L.; Diccianni, M. B. Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing. Leuk. Res. 2009, 33 (11), 1562-1566.
5. Lu, X.; Feng, X.; Man, X.; Yang, G.; Tang, L.; Du, D.; Zhang, F.; Yuan, H.; Huang, Q.; Zhang, Z.; Liu, Y.; Strand, D.; Chen, Z. Aberrant splicing of Hugl-1 is associated with hepatocellular carcinoma progression. Clin. Cancer Res. 2009, 15 (10), 3287-3296.
6. Stark, M.; Wichman, C.; Avivi, I.; Assaraf, Y. G. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009, 113 (18), 4362-4369.
7. Tazi, J.; Bakkour, N.; Stamm, S. Alternative splicing and disease. Biochim. Biophys. Acta 2009, 1792 (1), 14-26.
8. Vassen, L.; Khandanpour, C.; Ebeling, P.; van der Reijden, B. A.; Jansen, J. H.; Mahlmann, S.; Duhrsen, U.; Moroy, T. Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. Int. J. Hematol. 2009, 89 (4), 422-430.
9. Yang, G.; Huang, S. C.; Wu, J. Y.; Benz, E. J., Jr. Regulated Fox-2 isoform expression mediates protein 4. 1R splicing during erythroid differentiation. Blood 2008, 111 (1), 392-401.
10. Kalea, A. Z.; Schmidt, A. M.; Hudson, B. I. Alternative splicing of RAGE: roles in biology and disease. Front. Biosci. 2011, 17, 2756-2770.
11. Caballero OL, d. S. S., Brentani RR, Simpson AJ. Alternative spliced transcripts as cancer markers. Dis. Markers 2001, 17 (2), 67-75.
12. Barta, A.; Schumperli, D. Editorial on alternative splicing and disease. RNA Biol. 2010, 7 (4), 388-389.
13. David, A.; Mabjeesh, N.; Azar, I.; Biton, S.; Engel, S.; Bernstein, J.; Romano, J.; Avidor, Y.; Waks, T.; Eshhar, Z.; Langer, S. Z.; Lifschitz-Mercer, B.; Matzkin, H.; Rotman, G.; Toporik, A.; Savitsky, K.; Mintz, L. Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. J. Biol. Chem. 2002, 277 (20), 18084-18090.
14. Kote-Jarai, Z.; Amin Al Olama, A.; Leongamornlert, D.; Tymrakiewicz, M.; Saunders, E.; Guy, M.; Giles, G. G.; Severi, G.; Southey, M.; Hopper, J. L.; Sit, K. C.; Harris, J. M.; Batra, J.; Spurdle, A. B.; Clements, J. A.; Hamdy, F.; Neal, D.; Donovan, J.; Muir, K.; Pharoah, P. D.; Chanock, S. J.; Brown, N.; Benlloch, S.; Castro, E.; Mahmud, N.; O'Brien, L.; Hall, A.; Sawyer, E.; Wilkinson, R.; Easton, D. F.; Eeles, R. A. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum. Genet. 2011, 129 (6), 687-694.
15. Ommen, H. B.; Ostergaard, M.; Yan, M.; Braendstrup, K.; Zhang, D. E.; Hokland, P. Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse. Eur. J. Haematol. 2010, 84 (2), 128-132.
16. Yoshida, K.; Sanada, M.; Shiraishi, Y.; Nowak, D.; Nagata, Y.; Yamamoto, R.; Sato, Y.; Sato-Otsubo, A.; Kon, A.; Nagasaki, M.; Chalkidis, G.; Suzuki, Y.; Shiosaka, M.; Kawahata, R.; Yamaguchi, T.; Otsu, M.; Obara, N.; Sakata-Yanagimoto, M.; Ishiyama, K.; Mori, H.; Nolte, F.; Hofmann, W. K.; Miyawaki, S.; Sugano, S.; Haferlach, C.; Koeffler, H. P.; Shih, L. Y.; Haferlach, T.; Chiba, S.; Nakauchi, H.; Miyano, S.; Ogawa, S. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478 (7367), 64-69.
17. Graubert, T. A.; Shen, D.; Ding, L.; Okeyo-Owuor, T.; Lunn, C. L.; Shao, J.; Krysiak, K.; Harris, C. C.; Koboldt, D. C.; Larson, D. E.; McLellan, M. D.; Dooling, D. J.; Abbott, R. M.; Fulton, R. S.; Schmidt, H.; Kalicki-Veizer, J.; O'Laughlin, M.; Grillot, M.; Baty, J.; Heath, S.; Frater, J. L.; Nasim, T.; Link, D. C.; Tomasson, M. H.; Westervelt, P.; DiPersio, J. F.; Mardis, E. R.; Ley, T. J.; Wilson, R. K.; Walter, M. J. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat. Genet. 2011, 44 (1), 53-57.
18. Chesnais, V.; Kosmider, O.; Damm, F.; Itzykson, R.; Bernard, O. A.; Solary, E.; Fontenay, M. Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia. Oncotarget 2012, 3 (11), 1284-1293.
19. Damm, F.; Nguyen-Khac, F.; Fontenay, M.; Bernard, O. A. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies. Leukemia 2012, 26 (9), 2027-2031.
20. Je, E. M.; Yoo, N. J.; Kim, Y. J.; Kim, M. S.; Lee, S. H. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. Int. J. Cancer 2013, 133 (1), 260-265.
21. Ogawa, S. Splicing factor mutations in myelodysplasia. Int. J. Hematol. 2012, 96 (4), 438-442.
22. Rozovski, U.; Keating, M.; Estrov, Z. The significance of spliceosome mutations in chronic lymphocytic leukemia. Leuk. Lymphoma 2013, 54 (7), 1364-1366.
23. Fialkow, P. J.; Jacobson, R. J.; Papayannopoulou, T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977, 63, (1), 125-130.
24. Nowell, P. C. Preleukemia. Cytogenetic clues in some confusing disorders. Am J Pathol 1977, 89, (2), 459-476.
25. de Klein, A.; van Kessel, A. G.; Grosveld, G.; Bartram, C. R.; Hagemeijer, A.; Bootsma, D.; Spurr, N. K.; Heisterkamp, N.; Groffen, J.; Stephenson, J. R. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982, 300, (5894), 765-767.
26. Bartram, C. R.; de Klein, A.; Hagemeijer, A.; van Agthoven, T.; Geurts van Kessel, A.; Bootsma, D.; Grosveld, G.; Ferguson-Smith, M. A.; Davies, T.; Stone, M. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983, 306 (5940), 277-280.
27. Melo, J. V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996, 88 (7), 2375-2384.
28. van Rhee, F.; Hochhaus, A.; Lin, F.; Melo, J. V.; Goldman, J. M.; Cross, N. C. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 1996, 87 (12), 5213-5217.
29. Melo, J. V. BCR-ABL gene variants. Baillieres Clin. Haematol. 1997, 10 (2), 203-222.
30. Pane, F.; Frigeri, F.; Sindona, M.; Luciano, L.; Ferrara, F.; Cimino, R.; Meloni, G.; Saglio, G.; Salvatore, F.; Rotoli, B. Neutrophilicchronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996, 88 (7), 2410-2414.
31. Marcelle, C.; Gale, R. P.; Prokocimer, M.; Berrebi, A.; Merle-Beral, H.; Canaani, E. Analysis of BCR-ABL mRNA in chronic myelogenous leukemia patients and identification of a new BCRrelated sequence in human DNA. Genes, chromosomes & cancer 1989, 1 (2), 172-179.
32. Muller, A. J.; Witte, O. N. The 5' noncoding region of the human leukemia-associated oncogene BCR/ABL is a potent inhibitor of in vitro translation. Mol. Cell Biol. 1989, 9 (11), 5234-5238.
33. Beran, M.; Cao, X.; Estrov, Z.; Jeha, S.; Jin, G.; O'Brien, S.; Talpaz, M.; Arlinghaus, R. B.; Lydon, N. B.; Kantarjian, H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190, 000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res. 1998, 4 (7), 1661-1672.
34. Wilson, G.; Frost, L.; Goodeve, A.; Vandenberghe, E.; Peake, I.; Reilly, J. BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia. Blood 1997, 89 (8), 3064.
35. Volpe, G.; Cignetti, A.; Panuzzo, C.; Kuka, M.; Vitaggio, K.; Brancaccio, M.; Perrone, G.; Rinaldi, M.; Prato, G.; Fava, M.; Geuna, M.; Pautasso, M.; Casnici, C.; Signori, E.; Tonon, G.; Tarone, G.; Marelli, O.; Fazio, V. M.; Saglio, G. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. Cancer Res. 2007, 67 (11), 5300-5307.
36. Ma, W.; Giles, F.; Zhang, X.; Wang, X.; Zhang, Z.; Lee, T. S.; Yeh, C. H.; Albitar, M. Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors. Int. J. Lab. Hematol. 2011, 33 (3), 326-331.
37. Gruber, F. X.; Lundan, T.; Goll, R.; Silye, A.; Mikkola, I.; Rekvig, O. P.; Knuutila, S.; Remes, K.; Gedde-Dahl, T.; Porkka, K.; Hjorth-Hansen, H. BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations? Med. Oncol. 2012, 29 (1), 219-226.
38. Haber, D. A.; Sohn, R. L.; Buckler, A. J.; Pelletier, J.; Call, K. M.; Housman, D. E. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc. Natl. Acad. Sci. U. S. A. 1991, 88 (21), 9618-9622.
39. Dougherty, G. J.; Landorp, P. M.; Cooper, D. L.; Humphries, R. K. Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte "homing" receptor expressed by hemopoietic cells. J. Exp. Med. 1991, 174 (1), 1-5.
40. Harada, H.; Kondo, T.; Ogawa, S.; Tamura, T.; Kitagawa, M.; Tanaka, N.; Lamphier, M. S.; Hirai, H.; Taniguchi, T. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 1994, 9 (11), 3313-3320.
41. Foti, A.; Bar-Eli, M.; Ahuja, H. G.; Cline, M. J. A splicing mutation accounts for the lack of p53 gene expression in a CML blast crisis cell line: a novel mechanism of p53 gene inactivation. Br. J. Haematol. 1990, 76 (1), 143-145.
42. Nakai, H.; Kaneko, H.; Horiike, S.; Ariyama, Y.; Misawa, S.; Kashima, K.; Ishizaki, K. Multiple aberrant splicing of the p53 transcript without genomic mutations around exon-intron junctions in a case of chronic myelogenous leukaemia in blast crisis: a possible novel mechanism of p53 inactivation. Br. J. Haematol. 1994, 87 (4), 839-842.
43. Krainer, A. R.; Mayeda, A.; Kozak, D.; Binns, G. Functional expression of cloned human splicing factor SF2: homology to RNA-binding proteins, U1 70K, and Drosophila splicing regulators. Cell 1991, 66 (2), 383-394.
44. Grabowski, P. J.; Black, D. L. Alternative RNA splicing in the nervous system. Prog. Neurobiol. 2001, 65 (3), 289-308.
45. Black, D. L. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 2003, 72, 291-336.
46. Simon, R.; Radmacher, M. D.; Dobbin, K.; McShane, L. M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl. Cancer Inst. 2003, 95 (1), 14-18.
47. Modrek, B.; Lee, C. A genomic view of alternative splicing. Nat. Genet. 2002, 30 (1), 13-19.
48. Hastings, M. L.; Krainer, A. R. Pre-mRNA splicing in the new millennium. Curr. Opin. Cell Biol. 2001, 13 (3), 302-309.
49. Cech, T. R.; Moras, D.; Nagai, K.; Williamson, J. R. The RNA World. 2006.
50. Moore, M.; Query, C. C.; Sharp, P. Splicing of precursors to mRNA by the splicesome: Cold Spring Harbor Laboratory Press; 1993.
51. Nissim-Rafinia, M.; Kerem, B. Splicing regulation as a potential genetic modifier. Trends Genet. 2002, 18 (3), 123-127.
52. Jurica, M. S.; Moore, M. J. Pre-mRNA splicing: awash in a sea of proteins. Mol. Cell 2003, 12 (1), 5-14.
53. Blencowe, B. J. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem. Sci. 2000, 25 (3), 106-110.
54. Liu, H. X.; Zhang, M.; Krainer, A. R. Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins. Genes Dev. 1998, 12 (13), 1998-2012.
55. Graveley, B. R. Sorting out the complexity of SR protein functions. RNA 2000, 6 (9), 1197-1211.
56. Graveley, B. R.; Hertel, K. J.; Maniatis, T. The role of U2AF35 and U2AF65 in enhancer-dependent splicing. RNA 2001, 7 (6), 806-818.
57. Robberson, B. L.; Cote, G. J.; Berget, S. M. Exon definition may facilitate splice site selection in RNAs with multiple exons. Mol. Cell Biol. 1990, 10 (1), 84-94.
58. Zuo, P.; Maniatis, T. The splicing factor U2AF35 mediates critical protein-protein interactions in constitutive and enhancer-dependent splicing. Genes Dev. 1996, 10 (11), 1356-1368.
59. Matlin, A. J.; Clark, F.; Smith, C. W. Understanding alternative splicing: towards a cellular code. Nat. Rev. Mol. Cell Biol. 2005, 6 (5), 386-398.
60. Bourgeois, C. F.; Lejeune, F.; Stevenin, J. Broad specificity of SR (serine/arginine) proteins in the regulation of alternative splicing of pre-messenger RNA. Prog. Nucleic Acid Res. Mol. Biol. 2004, 78 37-88.
61. Amendt, B. A.; Si, Z. H.; Stoltzfus, C. M. Presence of exon splicing silencers within human immunodeficiency virus type 1 tat exon 2 and tat-rev exon 3: evidence for inhibition mediated by cellular factors. Mol. Cell Biol. 1995, 15 (11), 6480.
62. Del Gatto-Konczak, F.; Olive, M.; Gesnel, M. C.; Breathnach, R. hnRNP A1 recruited to an exon in vivo can function as an exon splicing silencer. Mol. Cell Biol. 1999, 19 (1), 251-260.
63. Zheng, Z. M.; Huynen, M.; Baker, C. C. A pyrimidine-rich exonic splicing suppressor binds multiple RNA splicing factors and inhibits spliceosome assembly. Proc. Natl. Acad. Sci. U. S. A. 1998, 95 (24), 14088-14093.
64. Caceres, J. F.; Kornblihtt, A. R. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 2002, 18 (4), 186-193.
65. Zahler, A. M.; Neugebauer, K. M.; Lane, W. S.; Roth, M. B. Distinct functions of SR proteins in alternative pre-mRNA splicing. Science 1993, 260 (5105), 219-222.
66. Dreyfuss, G.; Kim, V. N.; Kataoka, N. Messenger-RNA-binding proteins and the messages they carry. Nat. Rev. Mol. Cell Biol. 2002, 3 (3), 195-205.
67. Krecic, A. M.; Swanson, M. S. hnRNP complexes: composition, structure, and function. Curr. Opin. Cell Biol. 1999, 11 (3), 363-371.
68. Pagani, F.; Baralle, F. E. Genomic variants in exons and introns: identifying the splicing spoilers. Nat. Rev. Genet. 2004, 5 (5), 389-396.
69. Smith, C. W.; Valcarcel, J. Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem. Sci. 2000, 25 (8), 381-388.
70. Wagner, E. J.; Garcia-Blanco, M. A. Polypyrimidine tract binding protein antagonizes exon definition. Mol. Cell Biol. 2001, 21 (10), 3281-3288.
71. Cartegni, L.; Chew, S. L.; Krainer, A. R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 2002, 3 (4), 285-298.
72. Kuivenhoven, J. A.; Weibusch, H.; Pritchard, P. H.; Funke, H.; Benne, R.; Assmann, G.; Kastelein, J. J. An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease). J. Clin. Invest. 1996, 98 (2), 358-364.
73. Jiang, Z.; Cote, J.; Kwon, J. M.; Goate, A. M.; Wu, J. Y. Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with parkinsonism linked to chromosome 17. Mol. Cell Biol. 2000, 20 (11), 4036-4048.
74. Coutinho, G.; Xie, J.; Du, L.; Brusco, A.; Krainer, A. R.; Gatti, R. A. Functional significance of a deep intronic mutation in the ATM gene and evidence for an alternative exon 28a. Hum. Mutat. 2005, 25 (2), 118-124.
75. Bromidge, T.; Lowe, C.; Prentice, A.; Johnson, S. p53 intronic point mutation, aberrant splicing and telomeric associations in a case of B-chronic lymphocytic leukaemia. Br. J. Haematol. 2000, 111 (1), 223-229.
76. Faustino, N. A.; Cooper, T. A. Pre-mRNA splicing and human disease. Genes Dev. 2003, 17, (4), 419-437.
77. Syken, J.; De-Medina, T.; Munger, K. TID1, a human homolog of the Drosophila tumor suppressor l(2)tid, encodes two mitochondrial modulators of apoptosis with opposing functions. Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (15), 8499-8504.
78. Wu, J. Y.; Tang, H.; Havlioglu, N. Alternative pre-mRNA splicing and regulation of programmed cell death. Prog. Mol. Subcell Biol. 2003, 31, 153-185.
79. Jang, J. H. Identification and characterization of soluble isoform of fibroblast growth factor receptor 3 in human SaOS-2 osteosarcoma cells. Biochem. Biophys. Res. Commun. 2002, 292 (2), 378-382.
80. Brinkman, B. M. Splice variants as cancer biomarkers. Clin. Biochem. 2004, 37 (7), 584-594.
81. Venables, J. P. Aberrant and alternative splicing in cancer. Cancer Res. 2004, 64 (21), 7647-7654.
82. Stroomer, J. W.; Roos, J. C.; Sproll, M.; Quak, J. J.; Heider, K. H.; Wilhelm, B. J.; Castelijns, J. A.; Meyer, R.; Kwakkelstein, M. O.; Snow, G. B.; Adolf, G. R.; van Dongen, G. A. Safety and biodistribution of 99m Technetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin. Cancer Res. 2000, 6 (8), 3046-3055.
83. Aaltomaa, S.; Lipponen, P.; Ala-Opas, M.; Kosma, V. M. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur. Urol. 2001, 39 (2), 138-144.
84. Iczkowski, K. A.; Bai, S.; Pantazis, C. G. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. Anticancer Res. 2003, 23 (4), 3129-3140.
85. Lee, S. C.; Harn, H. J.; Lin, T. S.; Yeh, K. T.; Liu, Y. C.; Tsai, C. S.; Cheng, Y. L. Prognostic significance of CD44v5 expression in human thymic epithelial neoplasms. Ann. Thorac. Surg. 2003, 76 (1), 213-218; discussion 218.
86. Herrera-Gayol, A.; Jothy, S. Adhesion proteins in the biology of breast cancer: contribution of CD44. Exp. Mol. Pathol. 1999, 66 (2), 149-156.
87. Hsieh, H. F.; Yu, J. C.; Ho, L. I.; Chiu, S. C.; Harn, H. J. Molecular studies into the role of CD44 variants in metastasis in gastric cancer. Mol. Pathol. 1999, 52 (1), 25-28.
88. Naor, D.; Nedvetzki, S.; Golan, I.; Melnik, L.; Faitelson, Y. CD44 in cancer. Crit. Rev. Clin. Lab Sci. 2002, 39 (6), 527-579.
89. Sneath, R. J.; Mangham, D. C. The normal structure and function of CD44 and its role in neoplasia. Mol. Pathol. 1998, 51 (4), 191-200.
90. Wallach, S. B.; Friedmann, A.; Naor, D. The CD44 receptor of the mouse LB T-cell lymphoma: analysis of the isoform repertoire and ligand binding properties by reverse-transcriptase polymerase chain reaction and antisense oligonucleotides. Cancer Detect. Prev. 2000, 24 (1), 33-45.
91. Wittig, B. M.; Goebel, R.; Weg-Remers, S.; Pistorius, G.; Feifel, G.; Zeitz, M.; Stallmach, A. Stage-specific alternative cplicing of CD44 and alpha 6 beta 1 integrin in colorectal tumorigenesis. Exp. Mol. Pathol. 2001, 70 (2), 96-102.
92. Bartel, F.; Taubert, H.; Harris, L. C. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002, 2 (1), 9-15.
93. Hori, M.; Shimazaki, J.; Inagawa, S.; Itabashi, M.; Hori, M. Alternatively spliced MDM2 transcripts in human breast cancer in relation to tumor necrosis and lymph node involvement. Pathol. Int. 2000, 50 (10), 786-792.
94. Bartel, F.; Meye, A.; Wurl, P.; Kappler, M.; Bache, M.; Lautenschlager, C.; Grunbaum, U.; Schmidt, H.; Taubert, H. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma. Int. J. Cancer 2001, 95 (3), 168-175.
95. Lukas, J.; Gao, D. Q.; Keshmeshian, M.; Wen, W. H.; Tsao-Wei, D.; Rosenberg, S.; Press, M. F. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 2001, 61 (7), 3212-3219.
96. Matsumoto, R.; Tada, M.; Nozaki, M.; Zhang, C. L.; Sawamura, Y.; Abe, H. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res. 1998, 58 (4), 609-613.
97. Sigalas, I.; Calvert, A. H.; Anderson, J. J.; Neal, D. E.; Lunec, J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med. 1996, 2 (8), 912-917.
98. Evans, S. C.; Viswanathan, M.; Grier, J. D.; Narayana, M.; El-Naggar, A. K.; Lozano, G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 2001, 20 (30), 4041-4049.
99. Dang, J.; Kuo, M. L.; Eischen, C. M.; Stepanova, L.; Sherr, C. J.; Roussel, M. F. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res. 2002, 62 (4), 1222-1230.
100. Kraus, A.; Neff, F.; Behn, M.; Schuermann, M.; Muenkel, K.; Schlegel, J. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells. Int. J. Cancer 1999, 80 (6), 930-934.
101. Ponta, H.; Wainwright, D.; Herrlich, P. The CD44 protein family. Int. J. Biochem. Cell Biol. 1998, 30 (3), 299-305.
102. Mann, D. M.; Yamaguchi, Y.; Bourdon, M. A.; Ruoslahti, E. Analysis of glycosaminoglycan substitution in decorin by sitedirected mutagenesis. J. Biol. Chem. 1990, 265 (9), 5317-5323.
103. Nakai, H.; Misawa, S.; Taniwaki, M.; Horiike, S.; Takashima, T.; Seriu, T.; Nakagawa, H.; Fujii, H.; Shimazaki, C.; Maruo, N.; et al. Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemia. Br. J. Haematol. 1994, 87 (2), 425-427.
104. Willman, C. L.; Sever, C. E.; Pallavicini, M. G.; Harada, H.; Tanaka, N.; Slovak, M. L.; Yamamoto, H.; Harada, K.; Meeker, T. C.; List, A. F.; et al. Deletion of IRF-1, mapping to chromosome 5q31. 1, in human leukemia and preleukemic myelodysplasia. Science 1993, 259 (5097), 968-971.
105. Tamura, T.; Ishihara, M.; Lamphier, M. S.; Tanaka, N.; Oishi, I.; Aizawa, S.; Matsuyama, T.; Mak, T. W.; Taki, S.; Taniguchi, T. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995, 376 (6541), 596-599.
106. Romeo, G.; Fiorucci, G.; Chiantore, M. V.; Percario, Z. A.; Vannucchi, S.; Affabris, E. IRF-1 as a negative regulator of cell proliferation. J. Interferon Cytokine Res. 2002, 22 (1), 39-47.
107. Tanaka, N.; Ishihara, M.; Kitagawa, M.; Harada, H.; Kimura, T.; Matsuyama, T.; Lamphier, M. S.; Aizawa, S.; Mak, T. W.; Taniguchi, T. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994, 77 (6), 829-839.
108. Kimura, T.; Nakayama, K.; Penninger, J.; Kitagawa, M.; Harada, H.; Matsuyama, T.; Tanaka, N.; Kamijo, R.; Vilcek, J.; Mak, T. W.; et al. Involvement of the IRF-1 transcription factor in antiviral responses to interferons. Science 1994, 264 (5167), 1921-1924.
109. Taniguchi, T.; Lamphier, M. S.; Tanaka, N. IRF-1: the transcription factor linking the interferon response and oncogenesis. Biochim. Biophys. Acta 1997, 1333 (1), M9-17.
110. Tzoanopoulos, D.; Speletas, M.; Arvanitidis, K.; Veiopoulou, C.; Kyriaki, S.; Thyphronitis, G.; Sideras, P.; Kartalis, G.; Ritis, K. Low expression of interferon regulatory factor-1 and identification of novel exons skipping in patients with chronic myeloid leukaemia. Br. J. Haematol. 2002, 119 (1), 46-53.
111. Green, W. B.; Slovak, M. L.; Chen, I. M.; Pallavicini, M.; Hecht, J. L.; Willman, C. L. Lack of IRF-1 expression in acute promyelocytic leukemia and in a subset of acute myeloid leukemias with del(5)(q31). Leukemia 1999, 13 (12), 1960-1971.
112. Schaper, F.; Kirchhoff, S.; Posern, G.; Koster, M.; Oumard, A.; Sharf, R.; Levi, B. Z.; Hauser, H. Functional domains of interferon regulatory factor I (IRF-1). Biochem. J. 1998, 335 (Pt 1), 147-157.
113. Holtschke, T.; Lohler, J.; Kanno, Y.; Fehr, T.; Giese, N.; Rosenbauer, F.; Lou, J.; Knobeloch, K. P.; Gabriele, L.; Waring, J. F.; Bachmann, M. F.; Zinkernagel, R. M.; Morse, H. C., 3rd; Ozato, K.; Horak, I. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996, 87 (2), 307-317.
114. Schmidt, M.; Nagel, S.; Proba, J.; Thiede, C.; Ritter, M.; Waring, J. F.; Rosenbauer, F.; Huhn, D.; Wittig, B.; Horak, I.; Neubauer, A. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 1998, 91 (1), 22-29.
115. Garcon, L.; Lacout, C.; Svinartchouk, F.; Le Couedic, J. P.; Villeval, J. L.; Vainchenker, W.; Dumenil, D. Gfi-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells. Blood 2005, 105 (4), 1448-1455.
116. Osawa, M.; Yamaguchi, T.; Nakamura, Y.; Kaneko, S.; Onodera, M.; Sawada, K.; Jegalian, A.; Wu, H.; Nakauchi, H.; Iwama, A. Erythroid expansion mediated by the Gfi-1B zinc finger protein: role in normal hematopoiesis. Blood 2002, 100 (8), 2769-2777.
117. van der Meer, L. T.; Jansen, J. H.; van der Reijden, B. A. Gfi1 and Gfi1b: key regulators of hematopoiesis. Leukemia 24 (11), 1834-1843.
118. Laurent, B.; Randrianarison-Huetz, V.; Frisan, E.; Andrieu-Soler, C.; Soler, E.; Fontenay, M.; Dusanter-Fourt, I.; Dumenil, D. A short Gfi-1B isoform controls erythroid differentiation by recruiting the LSD1-CoREST complex through the dimethylation of its SNAG domain. J. Cell Sci. 2012, 125 (Pt 4), 993-1002.
119. Radich, J. P.; Dai, H.; Mao, M.; Oehler, V.; Schelter, J.; Druker, B.; Sawyers, C.; Shah, N.; Stock, W.; Willman, C. L.; Friend, S.; Linsley, P. S. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 2006, 103 (8), 2794-2799.
120. Jamieson, C. H.; Ailles, L. E.; Dylla, S. J.; Muijtjens, M.; Jones, C.; Zehnder, J. L.; Gotlib, J.; Li, K.; Manz, M. G.; Keating, A.; Sawyers, C. L.; Weissman, I. L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 2004, 351 (7), 657-667.
121. Polakis, P. Casein kinase 1: a Wnt'er of disconnect. Curr. Biol. 2002, 12 (14), R499-R501.
122. Polakis, P. Wnt signaling and cancer. Genes Dev. 2000, 14 (15), 1837-1851.
123. Dajani, R.; Fraser, E.; Roe, S. M.; Yeo, M.; Good, V. M.; Thompson, V.; Dale, T. C.; Pearl, L. H. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J. 2003, 22 (3), 494-501.
124. Kwok, J. B.; Hallupp, M.; Loy, C. T.; Chan, D. K.; Woo, J.; Mellick, G. D.; Buchanan, D. D.; Silburn, P. A.; Halliday, G. M.; Schofield, P. R. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann. Neurol. 2005, 58 (6), 829-839.
125. Yang, L.; Han, Y.; Suarez Saiz, F.; Minden, M. D. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007, 21 (5), 868-876.
126. Bruening, W.; Pelletier, J. A non-AUG translational initiation event generates novel WT1 isoforms. J. Biol. Chem. 1996, 271 (15), 8646-8654.
127. Scharnhorst, V.; Dekker, P.; van der Eb, A. J.; Jochemsen, A. G. Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties. J. Biol. Chem. 1999, 274 (33), 23456-23462.
128. Renshaw, J.; Orr, R. M.; Walton, M. I.; Te Poele, R.; Williams, R. D.; Wancewicz, E. V.; Monia, B. P.; Workman, P.; Pritchard-Jones, K. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival. Mol. Cancer Ther. 2004, 3 (11), 1467-1484.
129. Larsson, S. H.; Charlieu, J. P.; Miyagawa, K.; Engelkamp, D.; Rassoulzadegan, M.; Ross, A.; Cuzin, F.; van Heyningen, V.; Hastie, N. D. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 1995, 81 (3), 391-401.
130. Davies, R. C.; Bratt, E.; Hastie, N. D. Did nucleotides or amino acids drive evolutionary conservation of the WT1 +/-KTS alternative splice? Hum. Mol. Genet. 2000, 9 (8), 1177-1183.
131. Davies, R. C.; Calvio, C.; Bratt, E.; Larsson, S. H.; Lamond, A. I.; Hastie, N. D. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev. 1998, 12 (20), 3217-3225.
132. Gerald, W. L.; Rosai, J.; Ladanyi, M. Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc. Natl. Acad. Sci. U. S. A. 1995, 92 (4), 1028-1032.
133. Silberstein, G. B.; Van Horn, K.; Strickland, P.; Roberts, C. T., Jr.; Daniel, C. W. Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. Proc. Natl. Acad. Sci. U. S. A. 1997, 94 (15), 8132-8137.
134. Barbosa, A. S.; Hadjiathanasiou, C. G.; Theodoridis, C.; Papathanasiou, A.; Tar, A.; Merksz, M.; Gyorvari, B.; Sultan, C.; Dumas, R.; Jaubert, F.; Niaudet, P.; Moreira-Filho, C. A.; Cotinot, C.; Fellous, M. The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms' tumor. Hum. Mutat. 1999, 13 (2), 146-153.
135. Klamt, B.; Koziell, A.; Poulat, F.; Wieacker, P.; Scambler, P.; Berta, P.; Gessler, M. Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms. Hum. Mol. Genet. 1998, 7 (4), 709-714.
136. Kikuchi, H.; Takata, A.; Akasaka, Y.; Fukuzawa, R.; Yoneyama, H.; Kurosawa, Y.; Honda, M.; Kamiyama, Y.; Hata, J. Do intronic mutations affecting splicing of WT1 exon 9 cause Frasier syndrome? J. Med. Genet. 1998, 35 (1), 45-48.
137. Barbaux, S.; Niaudet, P.; Gubler, M. C.; Grunfeld, J. P.; Jaubert, F.; Kuttenn, F.; Fekete, C. N.; Souleyreau-Therville, N.; Thibaud, E.; Fellous, M.; McElreavey, K. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat. Genet. 1997, 17, (4), 467-470.
138. Liu, J. J.; Wang, Z. Y.; Deuel, T. F.; Xu, Y. H. Imbalanced expression of functionally different WT1 isoforms may contribute to sporadic unilateral Wilms' tumor. Biochem. Biophys. Res. Commun. 1999, 254 (1), 197-199.
139. Dallosso, A. R.; Hancock, A. L.; Brown, K. W.; Williams, A. C.; Jackson, S.; Malik, K. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours. Hum. Mol. Genet. 2004, 13 (4), 405-415.
140. Lopotova, T.; Polak, J.; Schwarz, J.; Klamova, H.; Moravcova, J. Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs. Blood Cells Mol. Dis. 2012, 49 (1), 41-47.
141. Lopotova, T.; Nadvornikova, S.; Zackova, M.; Polak, J.; Schwarz, J.; Klamova, H.; Moravcova, J. N-terminally truncated WT1 variant (sWT1) is expressed at very low levels in acute myeloid leukemia and advanced phases of chronic myeloid leukemia. Leuk. Res. 2012, 36 (4), e81-83.
142. Hahn, C. N.; Scott, H. S. Spliceosome mutations in hematopoietic malignancies. Nat. Genet. 2011, 44 (1), 9-10.
143. Thol, F.; Kade, S.; Schlarmann, C.; Loffeld, P.; Morgan, M.; Krauter, J.; Wlodarski, M. W.; Kolking, B.; Wichmann, M.; Gorlich, K.; Gohring, G.; Bug, G.; Ottmann, O.; Niemeyer, C. M.; Hofmann, W. K.; Schlegelberger, B.; Ganser, A.; Heuser, M. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012, 119 (15), 3578-3584.
144. Wu, S. J.; Kuo, Y. Y.; Hou, H. A.; Li, L. Y.; Tseng, M. H.; Huang, C. F.; Lee, F. Y.; Liu, M. C.; Liu, C. W.; Lin, C. T.; Chen, C. Y.; Chou, W. C.; Yao, M.; Huang, S. Y.; Ko, B. S.; Tang, J. L.; Tsay, W.; Tien, H. F. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood 2012.
145. Rossi, D.; Bruscaggin, A.; Spina, V.; Rasi, S.; Khiabanian, H.; Messina, M.; Fangazio, M.; Vaisitti, T.; Monti, S.; Chiaretti, S.; Guarini, A.; Del Giudice, I.; Cerri, M.; Cresta, S.; Deambrogi, C.; Gargiulo, E.; Gattei, V.; Forconi, F.; Bertoni, F.; Deaglio, S.; Rabadan, R.; Pasqualucci, L.; Foa, R.; Dalla-Favera, R.; Gaidano, G. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabinerefractoriness. Blood 2011, 118 (26), 6904-6908.
146. Quesada, V.; Conde, L.; Villamor, N.; Ordonez, G. R.; Jares, P.; Bassaganyas, L.; Ramsay, A. J.; Bea, S.; Pinyol, M.; Martinez-Trillos, A.; Lopez-Guerra, M.; Colomer, D.; Navarro, A.; Baumann, T.; Aymerich, M.; Rozman, M.; Delgado, J.; Gine, E.; Hernandez, J. M.; Gonzalez-Diaz, M.; Puente, D. A.; Velasco, G.; Freije, J. M.; Tubio, J. M.; Royo, R.; Gelpi, J. L.; Orozco, M.; Pisano, D. G.; Zamora, J.; Vazquez, M.; Valencia, A.; Himmelbauer, H.; Bayes, M.; Heath, S.; Gut, M.; Gut, I.; Estivill, X.; Lopez-Guillermo, A.; Puente, X. S.; Campo, E.; Lopez-Otin, C. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 2011, 44 (1), 47-52.
147. Thomas, A. N.; Pilkington, C. E.; Greer, R. Critical incident reporting in UK intensive care units: a postal survey. J. Eval. Clin. Pract. 2003, 9 (1), 59-68.
148. Aartsma-Rus, A.; Fokkema, I.; Verschuuren, J.; Ginjaar, I.; van Deutekom, J.; van Ommen, G. J.; den Dunnen, J. T. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat. 2009, 30 (3), 293-299.
149. Hammond, S. M.; Wood, M. J. Genetic therapies for RNA missplicing diseases. Trends Genet. 2011, 27 (5), 196-205.
150. O'Brien, K.; Matlin, A. J.; Lowell, A. M.; Moore, M. J. The biflavonoid isoginkgetin is a general inhibitor of Pre-mRNA splicing. J. Biol. Chem. 2008, 283 (48), 33147-33154.
151. Kotake, Y.; Sagane, K.; Owa, T.; Mimori-Kiyosue, Y.; Shimizu, H.; Uesugi, M.; Ishihama, Y.; Iwata, M.; Mizui, Y. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat. Chem. Biol. 2007, 3 (9), 570-575.
152. Kaida, D.; Motoyoshi, H.; Tashiro, E.; Nojima, T.; Hagiwara, M.; Ishigami, K.; Watanabe, H.; Kitahara, T.; Yoshida, T.; Nakajima, H.; Tani, T.; Horinouchi, S.; Yoshida, M. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of premRNA. Nat. Chem. Biol. 2007, 3 (9), 576-583.
153. Hasegawa, M.; Miura, T.; Kuzuya, K.; Inoue, A.; Won Ki, S.; Horinouchi, S.; Yoshida, T.; Kunoh, T.; Koseki, K.; Mino, K.; Sasaki, R.; Yoshida, M.; Mizukami, T. Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product. ACS Chem. Biol. 2011, 6 (3), 229-233.
154. Ngo, J. C.; Chakrabarti, S.; Ding, J. H.; Velazquez-Dones, A.; Nolen, B.; Aubol, B. E.; Adams, J. A.; Fu, X. D.; Ghosh, G. Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol. Cell 2005, 20 (1), 77-89.
155. Prasad, J.; Manley, J. L. Regulation and substrate specificity of the SR protein kinase Clk/Sty. Mol. Cell Biol. 2003, 23 (12), 4139-4149.
156. Chang, J. G.; Yang, D. M.; Chang, W. H.; Chow, L. P.; Chan, W. L.; Lin, H. H.; Huang, H. D.; Chang, Y. S.; Hung, C. H.; Yang, W. K. Small molecule amiloride modulates oncogenic RNA alternative splicing to devitalize human cancer cells. PLoS One 2011, 6 (6), e18643.